|
|
|
|
|
|
|
|
|
13.10.25 - 10:09
|
Corporate News: Fractus (EQS)
|
|
|
Fractus reicht im südlichen Bezirk von Kalifornien Klage wegen Patentverletzung gegen ResMed ein...
|
|
|
13.10.25 - 10:09
|
Corporate News: Fractus (EQS)
|
|
|
Fractus files patent infringement complaint against ResMed in the Southern District of California...
|
|
|
|
|
|
|
|
|
09.10.25 - 22:09
|
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025 (GlobeNewswire EN)
|
|
|
SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast....
|
|
|
09.10.25 - 14:03
|
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a patient enrolment update for the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as first line treatment for advanced or metastatic non-small cell lung cancer (1L NSCLC)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
